Lyell Immunopharma

Edit info

Founded: 2018

Location: South SF, CA

Employee range: 200 - 500

Clinical stage: Clin1

Therapy area: Multiple cancers

Drug types: ONC

Lead product: LYL797

Funding: $425M IPO Jun 2021

lyell.com

linkedin.com

job board

Drug notes:

LYL845 Clin1 multiple cancers; LYL119 RD/Clin0 solid tumors; undisclosed RD solid tumors

About:

Lyell Immunopharma is using the latest insights in immunology to reprogram T cells to cure cancer. CAR T cells have had most success so far in treating patients with B cell lymphomas. However, around 90% of all cancers are solid tumors where only limited success with cell therapies has been seen. Lyell is using their proprietary epigenetic and genetic reprogramming technologies to develop cell therapies to address these tumors for reliable and curative responses. Lyell’s approach involves identifying the “active ingredient” of adoptive cell therapies to either overcome loss of T cell function or to create T cell populations with durable stemness to infiltrate tumors. Lyell’s lead product, LYL797 is in Phase 1 clinical trials for non-small cell lung cancer, with other products in the pipeline.